

Government of the District of Columbia Department of Health



899 NORTH CAPITOL ST. NE – 2ND FLR. WASHINGTON, DC 20002

June 1, 2017

9:30am- 11:30 am

OPEN SESSION AGENDA

Board of Pharmacy Mission Statement:

"To protect and improve the public health through the efficient and effective regulation of the practice of Pharmacy and Pharmaceutical Detailing; through the licensure of Pharmacists, Pharmaceutical Detailers, Pharmacy Interns, and Pharmacy Technicians."

CALL TO ORDER:

PRESIDING:

BOARD MEMBERSHIP/ATTENDANCE:

BOARD MEMBERS:		
	DR .DAPHNE B. BERNARD, PHARM.D. R.PH CHAIRPERSON	
	MR. JAMES APPLEBY, R.PH VICE CHAIR	
	DR. TAMARA MCCANTS, PHARM.D. R.PH	
	DR. BENJAMIN MILES PHARM.D. R.PH	
	Mr. Alan Friedman, R.PH	
	MR. EMMANUEL BELLEGARDE, CONSUMER MEMBER	
	MR. EDDIE CURRY, CONSUMER MEMBER	
STAFF:	SHAUNA WHITE– EXECUTIVE DIRECTOR	
	KARIN BARRON-HEALTH LICENSING SPECIALIST	
	LATASHA GASKIN, HEALTH LICENSING SPECIALIST	
LEGAL STAFF:	CARLA WILLIAMS, ASSISTANT GENERAL COUNSEL	
VISITORS:		

Open Session Agenda

Quorum:

Introduction:		
0601-0-01	Approval of the Open Session Meeting Minutes May 4, 2017	
Consent Agenda	None	
Executive Director Report	Licensing Report Statistics Pharmacist and Technician Renewal Update	
Assistant General Counsel Report		Carla Williams
	None	
<u>Subcommittee</u> <u>Report</u>		Mr. Alan Friedman
	Legislative and Regulatory	
0601-O-02	Notice of Proposed Rulemaking –Collaborative Practice Agreement Regulations During the February Board meeting the moved to approve the revised	
	collaborative practice regulations as presented and to move forward with publication for consideration.	
0601-0-03	Communications Subcommittee Report	Dr. Daphne Bernard
0601-0-04	DOH Pharmacy Intern Presentation Pharmacy News	
NABP E- Newsletter	May 18, 2017	
	Safety of US Drug Supply Chain Threatened by Recent Congressional Importation Proposal, Indicates Former Director of FDA's Office of Criminal Investigations	
	DEA Reports Strong Turnout for 13 th Prescription Drug Take-Back Day	
	New, Dangerous Opioid Detected in Several States, Associated With Overdose Deaths	

	settlement agreements pursuant to § 2-575(b)(4); (Roll Call Vote)	
Motion to Adjourn the Open Session	Madam Chair, I move that the Board close the Open Public session portion of the meeting and move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the following purposes: to discuss disciplinary matters pursuant to § 2-575(b)(9); to seek the advice of counsel to the board, to preserve the attorney-client privilege, or to approve	
Comments from the Public		
<u>Matters for Board</u> Consideration	None	
	New FDA Drug Info Rounds Training Video Discusses the Definition of a Drug	
	Seventeen Accrediting Organizations Join HPAC as New Members of the Collaborative	
	Omaha PDAC Open to Nebraska Pharmacists	
	Utah Designates May `Talk To Your Pharmacist Month' to Encourage Dialogue About Opioid Prescriptions	
	Florida Governor Declares Public Health Emergency Due to Opioid Epidemic	
	New CDC Guide Shows Link Between Physicians and Pharmacists Working Together to Improve Patient Outcomes	
	FIP Report Shows Value of Pharmacists' Role in Consumers' Self-Care	
	A Former FBI Director Notes That Recent Drug Importation Proposal Increases Opportunity for Criminal Activity, Stress on Law Enforcement May 10, 2017	
	NACDS and HDA Oppose Prescription Drug Importation Proposal, Urge Congress to Protect Patients and Supply Chain	
	C.O. Truxton Expands Recall to Include More Products as a Precaution to Initial Label Mix-up Error	

This concludes the Public Open Session of the meeting. The Board will now move into the Closed Executive Session portion of the meeting pursuant to D.C. Official Code § 2-575(b) for the reasons set forth in the motion.

Open Session Meeting Adjourned at __:__